What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
Dr. John Cush RheumNow
3 years 3 months ago
Bullous Systemic Lupus Erythematosus (BSLE)
BSLE is a rare blistering cutaneous manifestation of systemic lupus erythematosus (SLE).
As goes SLE, bullous disease typically affects women, especially those of African descent.
https://t.co/TBr7pGXjZ5 https://t.co/aq5dX3wQPX
Dr. John Cush RheumNow
3 years 3 months ago
Record Use of Marijuana and Hallucinogens in Young Adults
The NY Times reports that a recent survey of drug use indicates that daily consumption of marijuana among young adults nearly doubled in the last decade.
https://t.co/Dvj4nUNdtg https://t.co/BRkq8nb5sz
Dr. John Cush RheumNow
3 years 3 months ago
Phase 2 RCTs are evaluating TLR 7 & TLR 8 blockade in SLE - BMS has afimetoran and Merck has enpatoran (both blocking TLR7/8) https://t.co/3TavS7NE99 https://t.co/lZyp1QLNqP
Dr. Jack Cush delivers this weeks rheumatology "weather report" with the best and least of news and journal articles from the past week on RheumNow.com
“Climate is what we expect, weather is what we get.” – Mark Twain
Dr. John Cush RheumNow
3 years 3 months ago
Myths & Misconceptions with Febrile Disorders
Still’s disease and autoinflammatory disorders are rare conditions unified by recurrent fevers and inflammation of skin, joints, and other organs.
https://t.co/vdZWR1cwDx https://t.co/OoGIBjpZGn
Dr. John Cush RheumNow
3 years 3 months ago
Top 60 brand-name drugs in US cost ~395%higher than other high-income countries. New legislation by Congress lets Medicare negotiate drug prices & cap out-of-pocket costs @$2,000/yr. Read more on proposed restrictions importing drugs from Canada https://t.co/z507qRNj4E https://t.co/kXnqIQkIp7
Dr. John Cush RheumNow
3 years 3 months ago
Study of 9611 pts w/ hip or knee arthroplasty for #OA tested aspirin (100 mg/d) vs enoxaparin (40 mg/d) (x35d w/THA; 14d after TKA). Enrollment prematurely halted as VTE rate was 3.45% w/ ASA and 1.8% w/ enoxaparin (superior to ASA: P= .007) https://t.co/jvuely8L56 https://t.co/O1TxCjaSPU
Dr. John Cush RheumNow
3 years 3 months ago
VTE (clots) w/ JAK inhibitors? Metanalysis of JAKi in 9711 Atopic dermatitits pts shows no significant assoc between JAK and incident VTE (HR 0.95; CI 0.62-1.45; or 0.23 VTE/100PYs). Actual #s: 3 VTE per 5722 pts (0.05%) https://t.co/VesXp5WSpY https://t.co/JsFSKzmbjN
Dr. John Cush RheumNow
3 years 3 months ago
Eval of 161 acute mono/oligoarthritis pts (gout, CPPD, controls) shows US of 2 joints (target jt, knee, MTP1, wrist) showed Dx accuracy (>90%), high specificity for gout (0.92-0.96) & CPPD (0.90-0.97); w/ sensitivity ranged from 0.73 to 0.85 for gout https://t.co/hW3pmz86kH https://t.co/IFVpINgybY
This week's NEJM has published the efficacy results of a large phase 3 trial of olokizumab, a humanized monoclonal antibody that directly targets IL-6 in patients with rheumatoid arthritis.
This is in contrast to two other marketed IL-6 inhibitors (sarilumab, tocilizumab) that bind to the IL-6 receptor.
In the United States, where over $300 million is spent annually on intraarticular hyaluronic acid injections, yet another study shows such therapy to be no better than placebo.
BMJ has published a metanalysis of the efficacy and safety of viscosupplementation (intraarticular hyaluronic acid injection) in knee osteoarthritis patients. This is one of many such reviews, all ending with the same conclusion.
Dr. John Cush RheumNow
3 years 3 months ago
NICE has approved upadacitinib (Rinvoq) for availability in England & Wales for use in adults w/ active ankylosing spondylitis not controlled with conventional therapy, only after TNF inhibitors are tried or not suitable https://t.co/MV47NPb2EF https://t.co/9Le2Sj5aNI
Dr. John Cush RheumNow
3 years 3 months ago
JAMA Patient Handout on common causes of patient hair loss
1. Patterned: androgenetic alopecia
2. Diffuse: telogen effluvium
3. Focal: alopecia areata
https://t.co/caL41RdxaV https://t.co/WsStH3drMk
Dr. John Cush RheumNow
3 years 3 months ago
Bidirectional Association Between Depression and Rheumatoid Arthritis
A recent meta-analysis suggests a bidirectional association between RA and depression. Finding RA patients with depression yields an 80% increased mortality risk.
https://t.co/1o2ObHd76V
Poster Hall